Depression in heart failure - A meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes

San Diego State University, San Diego, California, United States
Journal of the American College of Cardiology (Impact Factor: 15.34). 11/2006; 48(8):1527-37. DOI: 10.1016/j.jacc.2006.06.055
Source: PubMed

ABSTRACT This article describes a meta-analysis of published associations between depression and heart failure (HF) in regard to 3 questions: 1) What is the prevalence of depression among patients with HF? 2) What is the magnitude of the relationship between depression and clinical outcomes in the HF population? 3) What is the evidence for treatment effectiveness in reducing depression in HF patients? Key word searches of the Medline and PsycInfo databases, as well as reference searches in published HF and depression articles, identified 36 publications meeting our criteria. Clinically significant depression was present in 21.5% of HF patients, and varied by the use of questionnaires versus diagnostic interview (33.6% and 19.3%, respectively) and New York Heart Association-defined HF severity (11% in class I vs. 42% in class IV), among other factors. Combined results suggested higher rates of death and secondary events (risk ratio = 2.1, 95% confidence interval 1.7 to 2.6), trends toward increased health care use, and higher rates of hospitalization and emergency room visits among depressed patients. Treatment studies generally relied on small samples, but also suggested depression symptom reductions from a variety of interventions. In sum, clinically significant depression is present in at least 1 in 5 patients with HF; however, depression rates can be much higher among patients screened with questionnaires or with more advanced HF. The relationship between depression and poorer HF outcomes is consistent and strong across multiple end points. These findings reinforce the importance of psychosocial research in HF populations and identify a number of areas for future study.


Available from: Thomas Rutledge, May 30, 2015
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic heart failure (HF) is one of the most challenging problems in cardiology. Depression often coexists with HE It can develop at any stage of heart disease: as a response to the diagnosis, disease exacerbation or poor prognosis. There is evidence of common pathophysiological pathways in the two diseases: neurohormonal stimulation, arrhythmias, inflammation and blood hypercoagulability. Although the correlation between depression and poor HF prognosis is well recognised, it is still uncertain whether depression treatment can have a positive effect on HF course. It should be noted that tricyclic antidepressants cause orthostatic hypotension, tachycardia and conduction disorders. Most studies confirm the safety of use of selective serotonin reuptake inhibitors (SSRI), bupropion and venlafaxine in HF patients. In conclusion, the detection of depressive symptoms and the efficacy of depression therapy in HF patients is unsatisfactory. This is largely due to the diagnostic difficulties arising from similar clinical manifestations and lack of guidelines in patients suffering from both diseases.
    Polish journal of cardio-thoracic surgery 12/2012; 4(4):502-506. DOI:10.5114/kitp.2012.32694 · 0.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with heart failure (HF) experience multiple psychologic symptoms. Depression and anxiety are independently associated with survival. Whether co-morbid symptoms of anxiety and depression are associated with outcomes in patients with HF is unknown. To determine whether co-morbid symptoms of depression and anxiety are associated with all-cause mortality or rehospitalization for cardiac causes in patients with HF. A total of 1260 patients with HF participated in this study. Cox regression analysis was used to determine whether co-morbid symptoms of depression and anxiety independently predicted all-cause mortality and cardiac rehospitalization. Anxiety and depression were treated first as continuous-level variables, then as categorical variables using standard published cut points. Patients were then divided into 4 groups based on the presence of anxiety and depression symptoms. When entered as a continuous variable, the interaction between anxiety and depression (hazard ratio = 1.02; 95% CI: 1.01-1.03; p = 0.002) was a significant predictor of all-cause mortality in patients with HF. When entered as a categorical variable, co-morbid symptoms of depression and anxiety (vs no symptoms or symptoms of anxiety or depression alone) independently predicted all-cause mortality (hazard ratio = 2.59; 95% CI: 1.49-4.49; p = 0.001). None of the psychologic variables was a predictor of cardiac rehospitalization in patients with HF whether using the continuous or categorical level of measurement. To improve mortality outcomes in patients with HF, attention must be paid by health care providers to the assessment and management of co-morbid symptoms of depression and anxiety. Copyright © 2014 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.
    Psychosomatics 06/2014; DOI:10.1016/j.psym.2014.05.022 · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Depression is more common in patients with cardiovascular disease than in the general population. Conversely, depression is a risk factor for developing cardiovascular disease. Comorbidity of these two pathologies worsens prognosis. Several mechanisms have been indicated in the link between cardiovascular disease and depression, including inflammation. Systemic inflammation can have long-lasting effects on the central nervous system, which could be associated with depression. NGAL is an inflammatory marker and elevated plasma levels are associated with both cardiovascular disease and depression. While patients with depression show elevated NGAL levels, in patients with comorbid heart failure, NGAL levels are significantly higher and associated with depression scores. Systemic inflammation evokes NGAL expression in the brain. This is considered a proinflammatory effect as it is involved in microglia activation and reactive astrocytosis. Animal studies support a direct link between NGAL and depression/anxiety associated behavior. In this review we focus on the role of NGAL in linking depression and cardiovascular disease.
    Brain Behavior and Immunity 01/2015; 46. DOI:10.1016/j.bbi.2014.12.026 · 6.13 Impact Factor